184 related articles for article (PubMed ID: 28539250)
1. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis underlying resistance to Mps1/TTK inhibitors.
Koch A; Maia A; Janssen A; Medema RH
Oncogene; 2016 May; 35(19):2518-28. PubMed ID: 26364596
[TBL] [Abstract][Full Text] [Related]
4. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
6. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
[TBL] [Abstract][Full Text] [Related]
7. Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines.
Libouban MAA; de Roos JADM; Uitdehaag JCM; Willemsen-Seegers N; Mainardi S; Dylus J; de Man J; Tops B; Meijerink JPP; Storchová Z; Buijsman RC; Medema RH; Zaman GJR
Oncotarget; 2017 Jun; 8(24):38309-38325. PubMed ID: 28415765
[TBL] [Abstract][Full Text] [Related]
8. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
[TBL] [Abstract][Full Text] [Related]
9. Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures.
Hiruma Y; Koch A; Hazraty N; Tsakou F; Medema RH; Joosten RP; Perrakis A
J Biol Chem; 2017 Sep; 292(35):14496-14504. PubMed ID: 28726638
[TBL] [Abstract][Full Text] [Related]
10. Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Wang S; Zhang M; Liang D; Sun W; Zhang C; Jiang M; Liu J; Li J; Li C; Yang X; Zhou X
Eur J Med Chem; 2019 Aug; 175():247-268. PubMed ID: 31121430
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
13. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
14. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
15. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
[TBL] [Abstract][Full Text] [Related]
16. Insights into Resistance Mechanisms of Inhibitors to Mps1 C604Y Mutation via a Comprehensive Molecular Modeling Study.
Chen Y; Yu W; Jiang CC; Zheng JG
Molecules; 2018 Jun; 23(6):. PubMed ID: 29925769
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of reversine selectivity in inhibiting Mps1 more potently than aurora B kinase.
Hiruma Y; Koch A; Dharadhar S; Joosten RP; Perrakis A
Proteins; 2016 Dec; 84(12):1761-1766. PubMed ID: 27699881
[TBL] [Abstract][Full Text] [Related]
18. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
[TBL] [Abstract][Full Text] [Related]
19. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
[TBL] [Abstract][Full Text] [Related]
20. Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors.
Langdon SR; Westwood IM; van Montfort RL; Brown N; Blagg J
J Chem Inf Model; 2013 May; 53(5):1100-12. PubMed ID: 23672464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
